Casodex vs Placebo in Non-Metastatic Early Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

1,218

Participants

Timeline

Start Date

October 31, 1995

Study Completion Date

August 31, 2008

Conditions
Non-Metastatic Prostate Cancer
Interventions
DRUG

Bicalutamide

150mg p.o. daily

DRUG

Placebo

Trial Locations (54)

Unknown

Research Site, Aalborg

Research Site, Charlottenlund

Research Site, Copenhagen

Research Site, Esbjerg

Research Site, Frederiksberg

Research Site, Frederikssund

Research Site, Glostrup Municipality

Research Site, Herlev

Research Site, Holbuk

Research Site, NYK BING Falster

Research Site, Odense

Research Site, Orhus

Research Site, Randers

Research Site, S Nderborg

Research Site, Helsinki

Research Site, Joensuu

Research Site, Kokkola

Research Site, Kuopio

Research Site, Lahti

Research Site, Lappeenranta

Research Site, OYS (oulu)

Research Site, Tampere

Research Site, Turku

Research Site, Bergen

Research Site, BODU

Research Site, Drammen

Research Site, Fredrikstad

Research Site, Harstad

Research Site, Kristiansand

Research Site, Lesund

Research Site, Levanger

Research Site, Lillehammer

Research Site, Oslo

Research Site, Porsgrunn

Research Site, Rud

Research Site, Stavanger

Research Site, Strummen

Research Site, Tromsu

Research Site, Trondheim

Research Site, Tunsberg

Research Site, Gothenburg

Research Site, Govle

Research Site, Helsingborg

Research Site, Hudiksvall

Research Site, Junkoping

Research Site, Kristinehamn

Research Site, Luleå

Research Site, Malmu

Research Site, Norrköping

Research Site, Stockholm

Research Site, Urebro

Research Site, Ustersund

Research Site, VoSTEROS

Research Site, Vostervik

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Scandinavian Prostate Cancer Group

NETWORK

lead

AstraZeneca

INDUSTRY